Relapsing-Remitting Multiple Sclerosis and Human Herpesvirus 6 Active Infection
نویسندگان
چکیده
منابع مشابه
Relapsing-remitting multiple sclerosis and human herpesvirus 6 active infection.
BACKGROUND Recent studies have focused on the relationship between human herpesvirus 6 (HHV-6) and multiple sclerosis (MS). OBJECTIVE To analyze HHV-6 messenger RNA expression in patients with relapsing-remitting (RR) MS vs healthy blood donors (HBDs). DESIGN One hundred fifty-four subjects were enrolled in the study: 105 patients with RRMS (32 in relapse) and 49 HBDs. Total DNA and messeng...
متن کاملActive human herpesvirus 6 infection in patients with multiple sclerosis.
CONTEXT Human herpesvirus 6 (HHV-6) has been linked with multiple sclerosis (MS). OBJECTIVES To determine HHV-6 viral load in patients with MS, and to analyze separately its 2 variants, HHV-6A and HHV-6B. PATIENTS AND METHODS We analyzed 149 blood and serum samples; 103 were from patients with relapsing-remitting MS (33 during an MS relapse and 70 during remission), and 46 were from healthy...
متن کاملHuman herpesvirus 6 is latent in peripheral blood of patients with relapsing-remitting multiple sclerosis.
Studies of the association between HHV-6 and multiple sclerosis are hindered by the difficulty in discriminating between latent and active infection. A follow up study was undertaken of patients with multiple sclerosis, searching peripheral blood mononuclear cells for molecular markers associated with HHV-6 latency and lytic replication. The results show that HHV-6 is latent and did not support...
متن کاملAlemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
Alemtuzumab is a humanized monoclonal antibody directed against CD52 to deplete circulating T and B lymphocytes; lymphocyte depletion is followed by a distinctive pattern of T- and B-cell repopulation, changing the balance of the immune system. This review reports the efficacy and safety findings of the phase 2 CAMMS223 trial and the phase 3 CARE-MS I and II trials investigating alemtuzumab for...
متن کاملInterferons in relapsing remitting multiple sclerosis.
BACKGROUND Recombinant interferons have been shown to suppress both the clinical and magnetic resonance imaging (MRI) measures of disease activity in patients with relapsing remitting multiple sclerosis (RRMS). OBJECTIVES We performed a Cochrane review of all randomised, placebo-controlled trials of recombinant interferons in RRMS. SEARCH STRATEGY Of 208 articles identified by a predefined ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Neurology
سال: 2004
ISSN: 0003-9942
DOI: 10.1001/archneur.61.10.1523